Premier Path Wealth Partners LLC Has $515,000 Stake in Danaher Co. (NYSE:DHR)

Premier Path Wealth Partners LLC cut its position in Danaher Co. (NYSE:DHR) by 3.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,246 shares of the conglomerate’s stock after selling 73 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Danaher were worth $515,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Decker Retirement Planning Inc. bought a new stake in Danaher during the fourth quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher during the 3rd quarter worth $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the third quarter valued at about $50,000. Finally, Darwin Wealth Management LLC bought a new position in Danaher in the third quarter valued at about $55,000. Institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research reports. Evercore ISI increased their target price on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Raymond James dropped their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Scotiabank initiated coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 target price on the stock. Stifel Nicolaus increased their price target on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, UBS Group reduced their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Trading Down 1.4 %

DHR opened at $238.41 on Friday. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a fifty day moving average of $234.85 and a 200-day moving average of $253.32. The stock has a market cap of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same period last year, the company posted $2.02 EPS. The business’s quarterly revenue was up 3.1% on a year-over-year basis. On average, sell-side analysts predict that Danaher Co. will post 7.49 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s payout ratio is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.